Incidence of Acute Respiratory Failure (ARF) following Trimethoprim-Sulfamethoxazole (TMP-SMX) Use: A Descriptive Analysis

    Basic Details
    Date Posted
    Monday, December 21, 2020
    Status
    Complete
    Medical Product
    trimethoprim-sulfamethoxazole
    Health Outcome(s)
    acute respiratory failure
    Description

    In this report we examined counts of individuals using trimethoprim-sulfamethoxazole (TMP-SMX) and rates of acute respiratory failure (ARF) during treatment. We assessed indications for TMP-SMX dispensing as well as concurrent diagnoses at the time of ARF diagnoses. We repeated the analyses for four other antibiotics of interest.

    The study period included data from January 1, 2000 to December 31, 2019. We distributed this request to 14 Data Partners on May 15, 2020.

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2000 - December 31, 2019
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    Individuals 6 months to 64 years of age
    Data Sources
    Sentinel Distributed Database (SDD)